Articles and resources

Prenatal
28 Jul 2022

Revvity Tests Included in UK’s Updated NICE Diagnostic Guidance for Pre-Eclampsia DG-49

Two Revvity CE marked tests are recommended in latest version of NICE guidance “PLGF-based testing to help diagnose suspected preterm pre-eclampsia” for UK healthcare providers
World View Newborn Screening Congress
Newborn
05 May 2022

World View Newborn Screening Congress

We are very excited to announce the World View Newborn Screening Summit 2022 from 28-30th June in conjunction with International Neonatal Screening Day. There will be discussion around the latest advances in screening, but also hearing from those projects initiating new screening services. This event will have over 20 presentations from participants from 11 different countries. The sessions will be live streamed during the event and will be available ‘On-Demand’ after the event for those who register. Registration for the World View Newborn Screening Summit is free, and there will be opportunity to submit questions during the event to the speakers.
OZ Systems joins Revvity
Newborn
17 Dec 2021

OZ Systems joins Revvity

Oz Systems, the newborn screening software and interface provider, is now part of Revvity. OZ Systems is known for its expertise in developing cloud-based newborn blood spot, hearing and heart screening information management systems which improve patient care and intervention timeliness.
SMA Europe launches whitepaper
Newborn
01 Dec 2021

SMA Europe launches whitepaper

The European Alliance for SMA Newborn Screening has set out a goal to have Spinal Muscular Atrophy (SMA) included in all newborn screening programmes by 2025 To explain their position and learn more about the importance of SMA screening they have launched a whitepaper, which can be downloaded from their website. Follow link for the paper
First SMA baby identified with our screening solutions in Australia
Newborn
26 Apr 2021

First SMA baby identified with our screening solutions in Australia

A newborn baby has been identified as having SMA (spinal muscular atrophy) in Westmead Children’s Hospital in Australia, using a 4-plex SMA, SCID and XLA laboratory developed test

Products may not be licensed in accordance with the laws in all countries, such as the United States, Canada. Please check with your local representative for availability.

Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals.

Spin gif